

Phenotype: Cytochrome P450 (CYP 2C19) Poor Metabolizer | **Frequency:** 2-6% Caucasian, 13-19% Asian, 10-20% African

This table shows commonly prescribed medications with drug levels likely to be impacted by the patient phenotype indicated. This table doesn't list all affected medications nor does it take co-medication into account. For a personalized report based on the cumulative effect of all prescription drugs, OTCs, foods, herbals, and other relevant patient factors including DNA test results, enter the patient's date of birth and Genelex lab number at GeneMedRx.com/DNAlogin.

Drug Name	Indicator	Drug Name	Indicator	Drug Name	Indicator
aminopyrine	▲▲	escitalopram	▲▲	Prilosec	▲▲
amitriptyline	▲▲▲	esomeprazole	▲▲	primidone	▲▲
Atapryl	▲▲	etizolam	▲▲	metabolite phenobarbital	▲
Blocadren	▲▲	fluoxetine	▲▲	progesterone	▲▲
Budeprion XL	▲▲	gliclazide	▲▲	proguanil	▲▲
hydroxybupropion	▲	hexobarbital	▲▲	Prozac	▲▲
bupropion	▲▲	imipramine	▲▲	quazepam	▲▲
hydroxybupropion	▲	indisulam	▲▲	r-warfarin (1/10 as active)	▲▲
Carbox	▲▲	Istalol ophth	▲▲	sertraline	▲▲
carisoprodol	▲▲	Kapidex	▲▲	Silenor	▲▲
Celexa	▲▲	lansoprazole	▲▲	Soma	▲▲
citalopram	▲▲	Lexapro	▲▲	tenatoprazole	▲▲
clobazam	▲▲	Luminal	▲▲	terodiline	▲▲
norclobazam	▲▲	melatonin	▲▲	thalidomide	▲▲
clomipramine	▲▲	mephenytoin	▲▲	Thalomid	▲▲
clodigrel	▲▲	mephobarbital	▲▲	timolol	▲▲
cyclophosphamide	▲▲	methsuximide	▲▲	Tofranil	▲▲
4-hydroxycyclophosphamide	▲▲	moclobemide	▲▲	trimipramine	▲▲
Cytoxan	▲▲	nefinavir	▲▲	Valium	▲▲
4-hydroxycyclophosphamide	▲▲	Nexium	▲▲	voriconazole	▲▲
Dexilant	▲▲	Nilandron	▲▲	Wellbutrin	▲▲
diazepam	▲▲	nilutamide	▲▲	hydroxybupropion	▲
doxepin	▲▲	omeprazole	▲▲	Zelapar	▲▲
Eldepryl	▲▲	phenobarbital	▲▲	Zolof	▲▲
Endep	▲▲	Plavix	▲▲	Zonegran	▲▲
		Prevacid	▲▲	zonisamide	▲▲
		zotepine	▲▲		

Legend

Description	Indicator / Percent Change	Description	Indicator / Percent Change
Extreme Decrease	▼▲▲ -90% to -100% or - Major	Narrow therapeutic range, changes more likely to have a significant effect	▲▲
Substantial Decrease	▼▲▲ -60% to -90%	Predicted change from published clinical report	▲
Modest Decrease	▼▲▲ -25% to -60%	Prodrugs are taken in an inactive form and metabolized into an active form	▲
Minimal to No Change	▼▲▲ -25% to +25%	Increased Drug Exposure	▲
Modest increase	▲▲▲ +25% to -75%	Reduced Drug Exposure	▼
Substantial Increase	▲▲▲ +75% to +150%		
Extreme Increase	▲▲▲ Over +150% or + Major		
+ Some	▲▲ Unspecified Increase		
- Some	▼▲ Unspecified Decrease		

Help us improve: This supplementary report is a work in progress. If you have suggestions, please call Kristine at 206-826-1957 or email Kristine@genelex.com. This table is to be used as a tool to provide decision support and advisory input to clinical care by medical professionals. It is not designed to diagnose or treat any disease or other health condition. Only the physician is in a position to make a complete assessment of the patient and to judge the relevance of the information provided in the table to the actual clinical situation.

Genelex Corporation is Washington State Medical Test Site No. MTS-3919, CLIA No. 50D0980559, New York State Department of Health license no. PFI 8201, accredited by the American Association of Blood Banks since 1992, has contributed to the validation of National Institute of Standards and Technology Standard Reference Materials and is licensed to perform high complexity clinical testing in all US states. Distributed by Genelex Corporation 3000 First Ave., Suite One, Seattle, WA 98121 © Genelex, Corporation. 1997-2011